OBJECTIVE: To test the hypothesis that use of antihypertensive medication is associated with lower Alzheimer disease (AD) neuropathology. METHODS: This was a postmortem study of 291 brains limited to those with normal neuropathology or with uncomplicated AD neuropathology (i.e., without other dementia-associated neuropathology) in persons with or without hypertension (HTN) who were and were not treated with antihypertensive medications. Neuritic plaque (NP) and neurofibrillary tangle (NFT) densities, quantified in selected brain regions according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathologic criteria, with additional cortical NP counts, yielded 24 neuropathologic regional measures or summaries. Medicated hypertension (HTN-med; n = 77), nonmedicated HTN (HTN-nomed; n = 42), and non-HTN (no-HTN; n = 172) groups were compared by analyses of variance. RESULTS: The HTN-med group had significantly less neuropathology than the no-HTN group. The no-HTN group averaged over 50% higher mean NP and NFT ratings, and double the mean NP count, of the HTN-med group. The HTN-nomed group had significantly more neuropathology than the HTN-med group, but not significantly less than the no-HTN group. CONCLUSIONS: There was substantially less Alzheimer disease (AD) neuropathology in the medicated hypertension group than the nonhypertensive group, which may reflect a salutary effect of antihypertensive medication against AD-associated neuropathology.
OBJECTIVE: To test the hypothesis that use of antihypertensive medication is associated with lower Alzheimer disease (AD) neuropathology. METHODS: This was a postmortem study of 291 brains limited to those with normal neuropathology or with uncomplicated AD neuropathology (i.e., without other dementia-associated neuropathology) in persons with or without hypertension (HTN) who were and were not treated with antihypertensive medications. Neuritic plaque (NP) and neurofibrillary tangle (NFT) densities, quantified in selected brain regions according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathologic criteria, with additional cortical NP counts, yielded 24 neuropathologic regional measures or summaries. Medicated hypertension (HTN-med; n = 77), nonmedicated HTN (HTN-nomed; n = 42), and non-HTN (no-HTN; n = 172) groups were compared by analyses of variance. RESULTS: The HTN-med group had significantly less neuropathology than the no-HTN group. The no-HTN group averaged over 50% higher mean NP and NFT ratings, and double the mean NP count, of the HTN-med group. The HTN-nomed group had significantly more neuropathology than the HTN-med group, but not significantly less than the no-HTN group. CONCLUSIONS: There was substantially less Alzheimer disease (AD) neuropathology in the medicated hypertension group than the nonhypertensive group, which may reflect a salutary effect of antihypertensive medication against AD-associated neuropathology.
Authors: H Petrovitch; L R White; G Izmirilian; G W Ross; R J Havlik; W Markesbery; J Nelson; D G Davis; J Hardman; D J Foley; L J Launer Journal: Neurobiol Aging Date: 2000 Jan-Feb Impact factor: 4.673
Authors: A Ruitenberg; I Skoog; A Ott; O Aevarsson; J C Witteman; B Lernfelt; F van Harskamp; A Hofman; M M Breteler Journal: Dement Geriatr Cogn Disord Date: 2001 Jan-Feb Impact factor: 2.959
Authors: Ara S Khachaturian; Peter P Zandi; Constantine G Lyketsos; Kathleen M Hayden; Ingmar Skoog; Maria C Norton; JoAnn T Tschanz; Lawrence S Mayer; Kathleen A Welsh-Bohmer; John C S Breitner Journal: Arch Neurol Date: 2006-03-13
Authors: Ruth Peters; Nigel Beckett; Francoise Forette; Jaakko Tuomilehto; Robert Clarke; Craig Ritchie; Adam Waldman; Ivan Walton; Ruth Poulter; Shuping Ma; Marius Comsa; Lisa Burch; Astrid Fletcher; Christopher Bulpitt Journal: Lancet Neurol Date: 2008-07-07 Impact factor: 44.182
Authors: Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt Journal: N Engl J Med Date: 2008-03-31 Impact factor: 91.245
Authors: Vahram Haroutunian; Michal Schnaider-Beeri; James Schmeidler; Michael Wysocki; Dushyant P Purohit; Daniel P Perl; Leslie S Libow; Gerson T Lesser; Maria Maroukian; Hillel T Grossman Journal: Arch Neurol Date: 2008-09
Authors: Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan Journal: J Neurosci Date: 2010-08-25 Impact factor: 6.167
Authors: Linda Ferrington; Laura E Palmer; Seth Love; Karen J Horsburgh; Paul At Kelly; Patrick G Kehoe Journal: Am J Transl Res Date: 2012-04-12 Impact factor: 4.060
Authors: Jessica B S Langbaum; Kewei Chen; Lenore J Launer; Adam S Fleisher; Wendy Lee; Xiaofen Liu; Hillary D Protas; Stephanie A Reeder; Daniel Bandy; Meixiang Yu; Richard J Caselli; Eric M Reiman Journal: Neurobiol Aging Date: 2011-08-06 Impact factor: 4.673
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Florence F Roussotte; Prabha Siddarth; David A Merrill; Katherine L Narr; Linda M Ercoli; Jacqueline Martinez; Natacha D Emerson; Jorge R Barrio; Gary W Small Journal: Am J Geriatr Psychiatry Date: 2017-09-15 Impact factor: 4.105